HENRY FORD HEALTH SYSTEM

Lebrikizumab-lbkz (Ebyglyss) improves skin and itch in patients with moderate-to-severe atopic dermatitis previously treated with dupilumab, according to findings from the phase 3b ADapt study presented at the 2024 Fall Clinical Dermatology Conference. The IL-13 inhibitor showed 57% EASI-75 at 16 weeks and 60% at 24 weeks, with similar safety profile to previous studies.